Chinese University of Hong Kong: Kidney Diseases trials
The registry lists 15 Kidney Diseases studies with Chinese University of Hong Kong as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 3 3Phase 4 4No phase 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney DiseaseRecruitingNCT06727409Phase 4
- Archival of Human Biological Samples in CU-Med BiobankRecruitingNCT04706481
- Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavirCompletedNCT05624840
- Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus EntecavirActive, not recruitingNCT05423834
- Flash Glucose Monitoring in Reduction of Hypoglycaemia in Diabetic Patients with Chronic Kidney DiseaseCompletedNCT04016155Not applicable
- Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney DiseaseCompletedNCT03427801
- Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis PatientsWithdrawnNCT02168283Phase 4
- Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled TrialCompletedNCT01225445Phase 3
- To Assess the Accuracy of the eZscan Study in the Screening for Diabetic NephropathyCompletedNCT01163591
- A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic NephropathyTerminatedNCT00907608Not applicable
- Aliskiren for Immunoglobulin A (IgA) NephropathyCompletedNCT00870493Phase 3
- Paricalcitol for the Treatment of Immunoglobulin A NephropathyWithdrawnNCT00599963Phase 3
- Calcitriol in the Treatment of Immunoglobulin A (IgA) NephropathyCompletedNCT00319761Phase 4
- Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With NephropathyCompletedNCT00309127Not applicable
- The Use of Cilostazol in Patients With Diabetic NephropathyCompletedNCT00272831Phase 4